#United States #Oklahoma City #Biologics #Wheeler Bio #Rajesh Beri

Wheeler Bio Strengthens Leadership with Dr. Rajesh Beri

Wheeler Bio, Inc., an innovative contract development and manufacturing organization (CDMO), has taken a significant step forward in enhancing its scientific capabilities with the appointment of Dr. Rajesh Beri as the Chief Development Officer. This appointment signals Wheeler Bio's commitment to bolstering its expertise in biologics and the development of antibody-based therapeutics, catering to the evolving needs of its clinical and commercial clients.

Dr. Beri comes to Wheeler Bio with an impressive background, boasting over 30 years in the biotechnology sector. Throughout his career, he has led more than 70 successful biologics programs, advancing them from early research phases through to commercial manufacturing. His wealth of knowledge in CMC (Chemistry, Manufacturing, and Controls) strategy, coupled with his skills in technical operations and process development, is expected to significantly elevate the capabilities of Wheeler Bio's ModularCMC® platform. This initiative is designed to foster the accelerated development of biologics, ensuring that clients can scale operations while maintaining stringent regulatory compliance.

In a statement reflecting on the importance of this appointment, Patrick Lucy, President and CEO of Wheeler Bio, expressed enthusiasm about bringing Dr. Beri on board. He remarked, “Rajesh has built an exceptional career leading biologics development and advancing antibody-based molecules from early development through commercialization. His leadership will increase the scientific rigor at Wheeler Bio and ensure the excellent execution of process, formulation, and analytical development that our clients require.” This sentiment underscores the crucial role that leadership plays in driving organizational success, especially in the highly complex field of biologics.

Dr. Beri's educational credentials further highlight his suitability for this role; he earned a Ph.D. in Chemical Engineering from Worcester Polytechnic Institute and previously held senior leadership positions at notable companies such as Lonza Biologics, Immunovant, Goodwin Biotech, and Senda Biosciences. His extensive experience uniquely positions him to oversee Wheeler Bio's development organization, which integrates CMC programs from cell line development all the way through to Drug Substance and Drug Product manufacturing.

A key aspect of Dr. Beri's mandate will be to steer the scientific strategy underpinning Wheeler Bio's ModularCMC® platform. This will include an emphasis on continual improvement for delivering risk-mitigated, scalable solutions to partners, while also adhering to condensed timelines—a crucial element in the fast-paced world of drug development.

In Dr. Beri’s own words, he expressed excitement about his new role, stating, “I am honored to join Wheeler Bio during this exciting period of growth. The company's scientific depth, collaborative culture, and innovative ModularCMC® platform create an opportunity to help biotechnology companies overcome development challenges with flexible, phase-appropriate CMC solutions. I look forward to working alongside the talented Wheeler Bio team and providing technical support to Wheeler's partners to help advance their programs and ultimately deliver new therapies to patients.”

This strategic appointment further signifies Wheeler Bio's dedication to expanding its executive leadership team in response to increasing demand for U.S.-based biologics manufacturing. As the biotech landscape continues to evolve, investing in scientific expertise and enhancing development capabilities will be vital for success. The addition of Dr. Beri strengthens Wheeler Bio's High-Science, High-Touch corporate ethos, a principle that is foundational to building robust partnerships with clients.

About Wheeler Bio

Wheeler Bio stands out as a pioneer in contract development and manufacturing, having established its ModularCMC® platform, which streamlines the translation of antibody-based therapeutics from initial discovery through to clinical studies. This innovative approach ensures scalability while meeting advanced development and commercialization needs. Through the combination of a systematic work package framework and commitment to providing a comprehensive Common Technical Document (CTD) Module 3 for Investigational New Drug Applications (INDs), Wheeler Bio remains dedicated to accelerating drug discovery into clinical impact. Their ethos of High-Science, High-Touch exemplifies their commitment to not only meeting but exceeding client expectations.

In summary, the leadership of Dr. Rajesh Beri is directed towards fostering scientific rigor and enhancing the operational framework necessary for advancing biologics development, ultimately aiming to deliver significant new therapies to patients worldwide.